# Lecture 15: Health Care III, Redistribution Source: https://www.youtube.com/watch?v=dL7bXIUKzyg Recap page: https://rapidrecap.app/video/dL7bXIUKzyg Generated: 2026-02-04T20:06:13.01+00:00 --- ## Quick Overview The introduction of Medicare Advantage (Part C) aimed to shift risk from the government to private HMOs via capitated payments, initially set at 95% of traditional Medicare costs, but this immediately led to massive government losses due to adverse selection as only the healthiest enrollees enrolled, a problem exacerbated later when payments were raised to 120% of traditional costs, shifting the program's focus from cost-saving to expanding enrollment, while political barriers like replacing hidden employer taxes with overt taxes and entrenched industry interests prevent a straightforward transition to single-payer reform. **Key Points:** - Medicare Advantage plans operate as capitated arrangements where the government pays a fixed amount to HMOs, shedding financial risk, in exchange for enrollees accepting limited doctor networks but gaining coverage for Medicare cost-sharing, including uncapped doctor coinsurance. - Studies show Medicare Advantage delivers much less costly care than traditional fee-for-service Medicare without a meaningful negative effect on patient outcomes like mortality and hospitalizations. - The initial government strategy to pay 95% of the average traditional Medicare cost failed spectacularly because adverse selection caused only the healthiest people to enroll, leading the government to pay more for the selected group than the average cost baseline predicted, resulting in massive losses. - Following adjustments, including cutting the payment rate to 90% (which caused some plans to drop out) and later raising it to 120% of traditional Medicare costs (under the bill including Part D), enrollment in Medicare Advantage subsequently took off, becoming a major profit center for insurance companies. - Transitioning to single-payer healthcare faces three major political barriers: the difficulty of replacing the 'hidden tax' of employer-sponsored insurance (lower wages) with an overt tax, the political resistance from 80% of people unwilling to give up existing functional insurance (like the backlash to banning non-real insurance under the ACA), and the opposition from the entrenched $1.2 trillion insurance industry. - The concept of premium support, analogous to educational vouchers, offers government cost certainty by providing a fixed voucher amount, but this system can exacerbate equity issues as adverse selection causes the sickest people to end up in the most expensive plans, potentially leading to a death spiral. - Solving the two fundamental problems of health insurance markets—adverse selection and consumer confusion in choosing plans—is technically possible through risk adjustment (tying reimbursement to health level) and decision support tools (AI), but implementation remains extremely difficult in practice. **Context:** This lecture segment focuses on the governmental attempts in the early 1980s and beyond to control rapidly rising Medicare costs, specifically examining the introduction of managed care options known as Medicare Part C, now Medicare Advantage, run by private HMOs like Aetna and Humana. The discussion contrasts this managed care approach with traditional fee-for-service Medicare and then broadens to analyze the political feasibility of large-scale reforms like single-payer healthcare, using Massachusetts' individual mandate under Mitt Romney as a historical reference point for market-based solutions. ## Detailed Analysis The discussion details Medicare's shift toward managed care via Medicare Advantage (MA), where private insurers receive a fixed, age-dependent capitated payment from the government to cover care, thereby transferring risk away from the government. While studies confirm MA saves money without worsening core patient outcomes like mortality, the government's method of setting payment rates—initially 95% of the average traditional Medicare cost—created a severe adverse selection problem, as only healthier individuals enrolled, causing the government to lose massive amounts of money. Later legislative changes, including a temporary cut to 90% and then an increase to 120% of traditional costs, turned MA into a profit center, leading to its current enrollment of about half of all Medicare beneficiaries, contrary to the initial cost-saving motivation. The lecture then pivots to the broader political landscape of US healthcare reform, contrasting market-based solutions with single-payer. Professor Gruber argues that single-payer faces insurmountable political hurdles: the public resistance to replacing hidden employer insurance subsidies (lower wages) with overt taxes, the difficulty of displacing established systems favored by 80% of the population, and the powerful opposition from the existing insurance industry. Furthermore, choice in insurance markets introduces adverse selection and decision-making complexity, though both are technically solvable via risk adjustment and decision support tools, respectively, albeit with significant practical challenges in execution, as demonstrated by attempts to create risk-adjusted payments that plans still game. ### Medicare Advantage Structure and Effects - Enrollees trade limited doctor networks for elimination of Medicare cost-sharing; MA plans deliver less costly care than traditional Medicare without worsening mortality or hospitalizations. ### Adverse Selection Failure - Government lost money by paying 95% of the average cost because only the healthiest signed up, illustrating classic adverse selection where the pool's average cost rises post-selection. ### Political Barriers to Single Payer - Three intractable problems exist: replacing hidden employer tax subsidies with overt taxes is politically hard; people resist giving up existing insurance; and the $1.2 trillion insurance industry fights displacement. ### Premium Support and Equity Concerns - A voucher system offers government cost certainty but, due to adverse selection, results in the sick paying more for expensive plans, creating redistribution from sick to healthy individuals. ### Technical Solutions vs. Practical Reality - Adverse selection is theoretically solvable with risk adjustment (paying based on enrollee health), and choice confusion is solvable with decision support, but both face severe implementation difficulties. ### Innovation and Drug Pricing Trade-offs - Lowering pharmaceutical prices reduces R&D, but the welfare cost depends on what the savings fund; public R&D investment has declined significantly since the 1960s (from 2% of GDP to 0.5%). ### Regulating High-Cost Interventions - Calculating value using QALYs ($150,000 per QALY) works for standard drugs, but miraculous, multi-million dollar gene therapies (like the $2.1 million cure for SMA) strain this framework, forcing governments to ration access based on affordability.